Aetna’s Generic Gleevec Approach Combines Specialty Tiering, ‘Fail First’ Strategy
Executive Summary
Aetna oncology exec Kolodziej says the insurer expects the price discount for generic imatinib compared to the brand will be relatively modest at first.
You may also be interested in...
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.